Clinical trial · no report yet · Phase 3
EPCORE FL-1
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
- NCT05409066 ↗
- Active not recruiting
- Genmab
- 91 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 38 | |
| Podcasts | 25 | |
| X threads | 24 | |
| X videos | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- Epcoritamab; Rituximab; Lenalidomide
- Arms
- Epcoritamab Dose A in Combination With R2 · Experimental
- Epcoritamab Dose B in Combination With R2 · Experimental
- Lenalidomide and Rituximab (R2) · Active comparator
- Enrollment
- 549
- Primary outcomes
- Percentage of Participants Achieving Best Overall Response (BOR)
- Progression-Free Survival (PFS)
- Sponsor
- Genmab with AbbVie
- Start
- Sep 20, 2022
- Primary completion
- Dec 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05409066 · updated Jul 8, 2026
Publications
linked from the registry- Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jimenez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F; EPCORE FL-1 Investigators. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial. Lancet. 2026 Jan 10;407(10524):161-173. doi: 10.1016/S0140-6736(25)02360-8. Epub 2025 Dec 7. PubMed 41371238